DDInter222 DDInter1491
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib. Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thalidomide
Thalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Bortezomib {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Pomalidomide
Bortezomib {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Pomalidomide
Bortezomib {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Pomalidomide
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thalidomide
Thalidomide {u} (Compound) resembles {v} (Compound) Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Bortezomib {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Thalidomide
Thalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Bortezomib {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Bortezomib {u} (Compound) causes {v} (Side Effect) Dermatitis
Dermatitis {u} (Side Effect) is caused by {v} (Compound) Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Bortezomib {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Lenalidomide
Lenalidomide {u} (Compound) resembles {v} (Compound) Pomalidomide
Bortezomib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thalidomide
Thalidomide {u} (Compound) binds {v} (Gene) TNF
TNF {u} (Gene) is bound by {v} (Compound) Pomalidomide
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide (Compound) resembles Pomalidomide (Compound)
Bortezomib (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Pomalidomide (Compound)
Bortezomib (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Pomalidomide (Compound)
Bortezomib (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Pomalidomide (Compound)
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide (Compound) resembles Lenalidomide (Compound) and Lenalidomide (Compound) resembles Pomalidomide (Compound)
Bortezomib (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Thalidomide (Compound) and Thalidomide (Compound) resembles Pomalidomide (Compound)
Bortezomib (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Lenalidomide (Compound) and Lenalidomide (Compound) resembles Pomalidomide (Compound)
Bortezomib (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Lenalidomide (Compound) and Lenalidomide (Compound) resembles Pomalidomide (Compound)
Bortezomib (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Lenalidomide (Compound) and Lenalidomide (Compound) resembles Pomalidomide (Compound)
Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide (Compound) binds TNF (Gene) and TNF (Gene) is bound by Pomalidomide (Compound)